Endocrine therapy in combination with CDK4/6 inhibitors is the recommended first-line treatment for patients with hormone receptor (ER- and/or PR)–positive/HER2-negative metastatic breast disease without life-threatening disease. Chemotherapy is generally considered in further lines, when tumors develop endocrine resistance, or for patients with visceral crisis for whom a rapid response and tumor shrinkage are needed. Many endocrine agents are available (eg, fulvestrant, aromatase inhibitors, oral SERDs, etc.) that are usually administered in combination with targeted agents (CDK 4/6 inhibitors, PIK3CA inhibitors, mTOR inhibitors).
Learn more about the management of metastatic breast cancer.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Fast Five Quiz: Are You Prepared to Confront Metastatic Breast Cancer? - Medscape - Dec 15, 2022.